Literature DB >> 32706064

Long non-coding RNA OIP5-AS1 plays an oncogenic role in ovarian cancer through targeting miR-324-3p/NFIB axis.

Q-Y Liu1, X-X Jiang, H-N Tian, H-L Guo, H Guo, Y Guo.   

Abstract

OBJECTIVE: Long non-coding RNAs (lncRNAs) have been found to exert specific functions in the progression of ovarian cancer (OC), except for lncRNA-OIP5-AS1. In this study, we aim at exploring the molecular mechanisms of OIP5-AS1 in OC. PATIENTS AND METHODS: The expression levels of OIP5-AS1, miR-324-3p, and NFIB in OC tissues and OC cell lines were explored by qRT-PCR assay. The OC cell vitality was examined by CCK-8 and transwell assay. The protein expression level of NFIB was measured by Western blot analysis. The correlation between OIP5-AS1, miR-324-3p, and NFIB was appraised by Dual-Luciferase reporter assay.
RESULTS: OIP5-AS1 and NFIB were validated to be upregulated in both OC tissues and OC cell lines. Inversely, miR-324-3p downregulation was found in OC tissues and OC cell lines. Functionally, OIP5-AS1 knockdown and miR-324-3p overexpression restrained SKOV3 cell viability, invasion, and migration. Our results verified that OIP5-AS1 inhibited the expression of miR-324-3p in OC. Moreover, miR-324-3p directly targets NFIB. Besides that, NFIB silencing restrained the progression of SKOV3 cells.
CONCLUSIONS: The present study clarified that OIP5-AS1 accelerated OC progression by sponging miR-324-3p and upregulating NFIB. OIP5-AS1 can be a possible therapeutic target for the treatment of OC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32706064     DOI: 10.26355/eurrev_202007_21881

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Circ_0005925 Promotes Granulosa Cell Growth by Targeting MiR-324-3p to Upregulate MAP2K6 in Polycystic Ovary Syndrome.

Authors:  Peng Tu; Sujuan Yan; Fengping Zhang
Journal:  Biochem Genet       Date:  2022-06-11       Impact factor: 1.890

Review 2.  The role of lncRNA OIP5-AS1 in cancer development and progression.

Authors:  Cheng Zheng; Man Chu; Qiuli Chen; Cheng Chen; Zhi-Wei Wang; Xiao Chen
Journal:  Apoptosis       Date:  2022-03-22       Impact factor: 4.677

3.  microRNA-324-3p suppresses the aggressive ovarian cancer by targeting WNK2/RAS pathway.

Authors:  Fengjie Li; Zhen Liang; Yongqin Jia; Panyang Zhang; Kaijian Ling; Yanzhou Wang; Zhiqing Liang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Long non‑coding RNA OIP5‑AS1 facilitates the progression of ovarian cancer via the miR‑128‑3p/CCNG1 axis.

Authors:  Yuanyuan Liu; Xiaomin Fu; Xiuyun Wang; Yanling Liu; Xiaoyan Song
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 5.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

6.  Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K.

Authors:  Li Geng; Zhongqiu Wang; Yongju Tian
Journal:  J Ovarian Res       Date:  2022-01-03       Impact factor: 4.234

7.  Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6.

Authors:  Yujue Wang; Lingling Li; Xun Zhang; Xiaolan Zhao
Journal:  J Ovarian Res       Date:  2022-02-16       Impact factor: 4.234

Review 8.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.